Esperion Therapeutics, Inc. (ESPR) reported earnings of $0.22 per share for the fourth quarter, compared to a loss of $0.11 per share last year. The company generated $168.4M in revenue for the latest quarter.
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol in the United States. The company’s marketed products include NEXLETOL and NEXLIZET, oral once-daily non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
A detailed analysis of Esperion Therapeutics, Inc’s quarter follows shortly on AlphaStreet.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.